Scarica l'app Stockscreener
4.31
2.62%
0.11
Pre-mercato:
4.31
Precedente Chiudi:
$4.20
Aprire:
$4.2
Volume 24 ore:
1.22M
Relative Volume:
1.07
Capitalizzazione di mercato:
$319.92M
Reddito:
$6.96M
Utile/perdita netta:
$-46.51M
Rapporto P/E:
-25.12
EPS:
-0.1716
Flusso di cassa netto:
$-37.99M
1 W Prestazione:
+7.75%
1M Prestazione:
+24.57%
6M Prestazione:
+22.44%
1 anno Prestazione:
-65.90%
Intervallo 1D:
$4.20
$4.64
Intervallo di 1 settimana:
$3.75
$4.64
Portata 52W:
$1.60
$16.55
Perspective Therapeutics Inc Stock (CATX) Company Profile
Nome
Perspective Therapeutics Inc
Settore
Industria
Telefono
509-375-1202
Indirizzo
350 Hills Street, Suite 106, Richland
Confronta CATX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
4.31 | 296.91M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
124.42 | 229.71B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.78 | 154.35B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
387.32 | 149.60B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
89.70 | 114.97B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.56 | 45.92B | 5.54B | 4.18B | 623.10M | 7.00 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-11-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-01 | Iniziato | Wedbush | Outperform |
| 2024-09-25 | Iniziato | Truist | Buy |
| 2024-07-25 | Iniziato | BofA Securities | Buy |
| 2024-05-09 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Perspective Therapeutics Inc Borsa (CATX) Ultime notizie
Perspective Therapeutics Inc. Stock Analysis and ForecastExtraordinary performance - Autocar Professional
What drives Perspective Therapeutics Inc. stock priceTriple-digit wealth increases - Autocar Professional
Is Perspective Therapeutics Inc. a good long term investmentSkyrocketing returns - Autocar Professional
What analysts say about Perspective Therapeutics Inc. stockUnprecedented profit potential - jammulinksnews.com
Why Perspective Therapeutics Inc. stock attracts strong analyst attentionFree Best Performing Stock Alerts - Newser
How Perspective Therapeutics Inc. stock performs during market volatilityIntraday Trade Ideas - Newser
What makes Perspective Therapeutics Inc. stock price move sharplyHigh Return Setup Scanner - Newser
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results - The Manila Times
Cancer Treatment Pioneer Perspective Therapeutics Announces Q2 2025 Earnings Date: Key Updates Coming - Stock Titan
Top Reasons to Buy SBT(sbtcoin)Free Stock Market Practical Discussion Forums - newser.com
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Perspective Therapeutics Inc (CATX Stock: A Sea of Opportunity - investchronicle.com
Perspective Therapeutics Updates Strategic Focus on Radiopharmaceuticals - TipRanks
Perspective Therapeutics, Inc.(NYSEAM: CATX) dropped from Russell 3000 Growth Index - MarketScreener
Analysts Offer Insights on Healthcare Companies: BeiGene (ONC), Vertex Pharmaceuticals (VRTX) and Edgewise Therapeutics (EWTX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), Ocular Therapeutix (OCUL) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Perspective Therapeutics (CATX) Maintains 'Outperform' Rating by Wedbush | CATX Stock News - GuruFocus
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial - Yahoo Finance
Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going - Finansavisen
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Rating of “Buy” from Analysts - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Bank of America Corp DE - Defense World
Analyzing Ratios: Perspective Therapeutics Inc (CATX)’s Financial Story Unveiled - DWinneX
New Research Reveals Top 6 Radioligand Therapy Companies Transforming Cancer Treatment in $13B Market - Stock Titan
The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic - insights.citeline.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Warren Buffett Says Buy This Index Fund, and Here's How It Could Turn $500 Per Month Into $1 Million - The Globe and Mail
Cantor Fitzgerald Forecasts CATX FY2026 Earnings - Defense World
Ameriprise Financial Inc. Sells 645,170 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Stocks Sharply Higher on a Better-Than-Expected US May Payroll Report - The Globe and Mail
151,610 Shares in Perspective Therapeutics, Inc. (NYSE:CATX) Acquired by Two Sigma Advisers LP - Defense World
ProShare Advisors LLC Acquires 5,011 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics (NYSE:CATX) Rating Increased to Moderate Buy at Royal Bank of Canada - Defense World
3 Promising Penny Stocks With Market Caps Over $90M - simplywall.st
Perspective Therapeutics (CATX) Price Target Raised by RBC Capital | CATX Stock News - GuruFocus
Perspective Therapeutics (CATX) Gets a Buy from Scotiabank - The Globe and Mail
RBC Capital Boosts Price Target for Perspective Therapeutics (CA - GuruFocus
Perspective Therapeutics Updates on Radiopharmaceutical Advancements - TipRanks
RBC Capital raises Perspective Therapeutics stock price target to $16 By Investing.com - Investing.com Nigeria
RBC Raises Price Target on Perspective Therapeutics to $16 From $15, Keeps Outperform, Speculative Risk - marketscreener.com
RBC Capital raises Perspective Therapeutics stock price target to $16 - Investing.com
Perspective Therapeutics Inc Azioni (CATX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.15%
0.17%
Capitalizzazione:
|
Volume (24 ore):